> 2003 Publications
11.
PSA progression following radical prostatectomy and radiation
therapy: new standards in the new Millennium.
Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V.
Eur Urol. 43:12-27, 2003.
Abstract
| 
PDF
12.
Cancer-specific mortality after surgery or radiation
for patients with clinically localized prostate cancer managed
during the prostate-specific antigen era.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen
MH.
J Clin Oncol. 21:2163-72, 2003.
Abstract
|
PDF
13.
A novel neoplastic primary tumor-derived human prostate
epithelial cell line.
Ko D, Gu Y, Yasunaga Y, Nakamura K, Srivastava S, Moul JW, Sesterhenn
IA, McLeod DG, Arnstein P, Taylor DO, Hukku B, Rhim JS.
Int J Oncol. 22:1311-7, 2003.
Abstract
|
PDF
14. Methylation of TFPI-2 gene is not the sole cause of
its silencing.
Rao CN, Segawa T, Navari JR, Xu L, Srivastava S, Moul JW, Phillips
B.
Int J Oncol. 22:843-8, 2003.
Abstract
|
PDF
15. Limitations of tissue microarrays in the evaluation
of focal alterations of bcl-2 and p53 in whole mount derived prostate
tissues.
Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun
L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A,
Moul JW, Sesterhenn IA.
Oncol Rep. 10:223-8, 2003.
Abstract
|
PDF
16.
Duffy antigen facilitates movement of chemokine across
the endothelium in vitro and promotes neutrophil transmigration
in vitro and in vivo.
Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK,
Ruzinski JT, Rhim JS, Martin TR, Goodman RB.
Immunol. 170:5244-51, 2003.
Abstract
|
PDF
17.
Generation of immortal human prostate cell lines for the study
of prostate cancer.
Rhim JS.
Methods Mol Med. 81:69-77, 2003.
Abstract
18.
Limited value of bone scintigraphy and computed tomography
in assessing biochemical failure after radical prostatectomy.
Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB,
Foley JP, Riffenburgh RH, Moul JW.
Urology. 61:607-11, 2003.
Abstract
|
PDF
